A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)
Christopher Geven(Radboud University Nijmegen), Peter Pickkers(Radboud University Nijmegen), Oliver Hartmann, Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Matthijs Kox(Radboud University Medical Center), Gernot Marx(RWTH Aachen University), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Alice Blet(Inserm), Jens Zimmermann, P. Scigalla
Cited by 48
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k